Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHA:605266)
China · Delayed Price · Currency is CNY 18.04
+0.24 (1.35%)
May 29, 2026, 3:00 PM CST
SHA:605266 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 8,204 | 8,407 | 8,646 | 8,537 | 7,062 | 4,863 |
Other Revenue | 513.57 | 513.57 | 636.61 | 543.85 | 452.91 | 371.79 |
| 8,718 | 8,921 | 9,283 | 9,081 | 7,514 | 5,235 | |
Revenue Growth (YoY) | -5.89% | -3.90% | 2.23% | 20.84% | 43.54% | 17.21% |
Cost of Revenue | 5,584 | 5,726 | 5,993 | 5,845 | 4,829 | 3,373 |
Gross Profit | 3,133 | 3,195 | 3,290 | 3,236 | 2,685 | 1,862 |
Selling, General & Admin | 2,734 | 2,794 | 2,938 | 2,588 | 2,121 | 1,478 |
Other Operating Expenses | 12.36 | 10.86 | 26.11 | 10.64 | 13.46 | -3.22 |
Operating Expenses | 2,768 | 2,826 | 2,965 | 2,596 | 2,139 | 1,475 |
Operating Income | 365.46 | 368.73 | 324.7 | 639.62 | 546.65 | 386.78 |
Interest Expense | -117.71 | -120.72 | -135.37 | -121.23 | -99.92 | -49.8 |
Interest & Investment Income | 3.17 | 3.36 | 5.75 | 7.04 | 7.77 | 13.67 |
Currency Exchange Gain (Loss) | 0.46 | 0.46 | -0.1 | - | - | - |
Other Non Operating Income (Expenses) | -12.38 | -13.04 | -11.35 | -12.52 | -9.14 | -6.99 |
EBT Excluding Unusual Items | 239 | 238.79 | 183.62 | 512.91 | 445.36 | 343.66 |
Impairment of Goodwill | -34.52 | -34.52 | -11.01 | -4.77 | -4.64 | - |
Gain (Loss) on Sale of Investments | -6.42 | -7.46 | -9.1 | -7.94 | - | - |
Gain (Loss) on Sale of Assets | 7.71 | 6.17 | 7.26 | 9.85 | -1.09 | 0.19 |
Other Unusual Items | 4.25 | 4.17 | -1.82 | 12.64 | 1.1 | 14.38 |
Pretax Income | 210.03 | 207.16 | 168.95 | 522.7 | 440.74 | 358.23 |
Income Tax Expense | 59.51 | 59.04 | 40.99 | 108.21 | 66.28 | 58.97 |
Earnings From Continuing Operations | 150.52 | 148.12 | 127.96 | 414.49 | 374.46 | 299.26 |
Minority Interest in Earnings | 0.05 | 0.03 | 0.17 | -0.07 | -0.17 | 1.27 |
Net Income | 150.57 | 148.15 | 128.13 | 414.41 | 374.29 | 300.53 |
Net Income to Common | 150.57 | 148.15 | 128.13 | 414.41 | 374.29 | 300.53 |
Net Income Growth | 37.65% | 15.63% | -69.08% | 10.72% | 24.55% | 19.66% |
Shares Outstanding (Basic) | 147 | 148 | 154 | 154 | 151 | 140 |
Shares Outstanding (Diluted) | 147 | 148 | 154 | 155 | 152 | 140 |
Shares Change (YoY) | -4.25% | -4.03% | -0.17% | 1.91% | 8.55% | 21.58% |
EPS (Basic) | 1.02 | 1.00 | 0.83 | 2.69 | 2.48 | 2.15 |
EPS (Diluted) | 1.02 | 1.00 | 0.83 | 2.68 | 2.47 | 2.15 |
EPS Growth | 43.75% | 20.48% | -69.03% | 8.65% | 14.74% | -1.58% |
Free Cash Flow | 1,035 | 1,025 | 241.05 | 724.37 | 409.93 | 358.87 |
Free Cash Flow Per Share | 7.01 | 6.92 | 1.56 | 4.68 | 2.70 | 2.57 |
Dividend Per Share | 1.270 | 1.270 | 1.100 | 1.071 | 0.936 | 0.777 |
Dividend Growth | 15.46% | 15.46% | 2.73% | 14.41% | 20.51% | -10.98% |
Gross Margin | 35.94% | 35.82% | 35.44% | 35.64% | 35.73% | 35.57% |
Operating Margin | 4.19% | 4.13% | 3.50% | 7.04% | 7.27% | 7.39% |
Profit Margin | 1.73% | 1.66% | 1.38% | 4.56% | 4.98% | 5.74% |
Free Cash Flow Margin | 11.87% | 11.49% | 2.60% | 7.98% | 5.46% | 6.86% |
EBITDA | 435.79 | 440.07 | 400.08 | 707.38 | 599.54 | 417.79 |
EBITDA Margin | 5.00% | 4.93% | 4.31% | 7.79% | 7.98% | 7.98% |
D&A For EBITDA | 70.33 | 71.34 | 75.38 | 67.76 | 52.89 | 31.01 |
EBIT | 365.46 | 368.73 | 324.7 | 639.62 | 546.65 | 386.78 |
EBIT Margin | 4.19% | 4.13% | 3.50% | 7.04% | 7.27% | 7.39% |
Effective Tax Rate | 28.33% | 28.50% | 24.26% | 20.70% | 15.04% | 16.46% |
Revenue as Reported | 8,718 | 8,921 | 9,283 | 9,081 | 7,514 | 5,235 |
Advertising Expenses | - | 15.91 | 28.62 | 25.6 | 23.17 | 18.16 |